{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:58:37Z","timestamp":1771016317495,"version":"3.50.1"},"reference-count":294,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10620-018-5072-x","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T11:27:57Z","timestamp":1524050877000},"page":"1706-1725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management"],"prefix":"10.1007","volume":"63","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"5072_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bpg.2011.09.009","volume":"25","author":"R Liberal","year":"2011","unstructured":"Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Prac Res Clin Gastroenterol. 2011;25:653\u2013664.","journal-title":"Best Prac Res Clin Gastroenterol."},{"key":"5072_CR2","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s10620-015-3708-7","volume":"60","author":"AJ Czaja","year":"2015","unstructured":"Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci. 2015;60:2881\u20132900.","journal-title":"Dig Dis Sci."},{"key":"5072_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1034\/j.1600-0676.2001.021004225.x","volume":"21","author":"DP Bogdanos","year":"2001","unstructured":"Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225\u2013232.","journal-title":"Liver."},{"key":"5072_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/hep.22529","volume":"48","author":"DG Bowen","year":"2008","unstructured":"Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology. 2008;48:1013\u20131015.","journal-title":"Hepatology."},{"key":"5072_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaut.2011.06.005","volume":"37","author":"E Hintermann","year":"2011","unstructured":"Hintermann E, Holdener M, Bayer M, et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun. 2011;37:242\u2013253.","journal-title":"J Autoimmun."},{"key":"5072_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2012.11.001","volume":"42","author":"J Ehser","year":"2013","unstructured":"Ehser J, Holdener M, Christen S, et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun. 2013;42:39\u201349.","journal-title":"J Autoimmun."},{"key":"5072_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2249.1991.tb08164.x","volume":"84","author":"H Lohr","year":"1991","unstructured":"Lohr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297\u2013302.","journal-title":"Clin Exp Immunol."},{"key":"5072_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2249.1993.tb05996.x","volume":"94","author":"JF Schlaak","year":"1993","unstructured":"Schlaak JF, Lohr H, Gallati H, Meyer zum Buschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol. 1993;94:168\u2013173.","journal-title":"Clin Exp Immunol."},{"key":"5072_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00005176-199501000-00005","volume":"20","author":"G Maggiore","year":"1995","unstructured":"Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20:23\u201327.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"5072_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.510300412","volume":"30","author":"S Cookson","year":"1999","unstructured":"Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851\u2013856.","journal-title":"Hepatology."},{"key":"5072_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1023\/A:1005506031717","volume":"45","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028\u20131035.","journal-title":"Dig Dis Sci."},{"key":"5072_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1872-034X.2011.00773.x","volume":"41","author":"A Kamijo","year":"2011","unstructured":"Kamijo A, Yoshizawa K, Joshita S, et al. Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients. Hepatol Res. 2011;41:350\u2013357.","journal-title":"Hepatol Res."},{"key":"5072_CR13","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","volume":"142","author":"MS Longhi","year":"2012","unstructured":"Longhi MS, Liberal R, Holder B, et al. Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology. 2012;142:1526\u20131535.","journal-title":"Gastroenterology."},{"key":"5072_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1089\/jir.2013.0075","volume":"34","author":"A Landi","year":"2014","unstructured":"Landi A, Weismuller TJ, Lankisch TO, et al. Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J Interferon Cytokine Res. 2014;34:204\u2013214.","journal-title":"J Interferon Cytokine Res."},{"key":"5072_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5152\/tjg.2017.17501","volume":"28","author":"F Behfarjam","year":"2017","unstructured":"Behfarjam F, Sanati MH, Nasseri Moghaddam S, et al. Role of Th1\/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol. 2017;28:110\u2013114.","journal-title":"Turk J Gastroenterol."},{"key":"5072_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/apt.12825","volume":"40","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014;40:261\u2013279.","journal-title":"Aliment Pharmacol Ther."},{"key":"5072_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol."},{"key":"5072_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4\u2009+\u2009CD25\u2009+\u2009regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63\u201371.","journal-title":"J Autoimmun."},{"key":"5072_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hep.25682","volume":"56","author":"R Liberal","year":"2012","unstructured":"Liberal R, Grant CR, Holder BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway. Hepatology. 2012;56:677\u2013686.","journal-title":"Hepatology."},{"key":"5072_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaut.2012.12.003","volume":"41","author":"MS Longhi","year":"2013","unstructured":"Longhi MS, Ma Y, Grant CR, et al. T-regs in autoimmune hepatitis-systemic lupus erythematosus\/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile. J Autoimmun. 2013;41:146\u2013151.","journal-title":"J Autoimmun."},{"key":"5072_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/hep.27884","volume":"62","author":"R Liberal","year":"2015","unstructured":"Liberal R, Grant CR, Holder BS, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology. 2015;62:863\u2013875.","journal-title":"Hepatology."},{"key":"5072_CR22","doi-asserted-by":"publisher","first-page":"e0136908","DOI":"10.1371\/journal.pone.0136908","volume":"10","author":"K Migita","year":"2015","unstructured":"Migita K, Komori A, Kozuru H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One. 2015;10:e0136908.","journal-title":"PLoS One."},{"key":"5072_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1453356","author":"AJ Czaja","year":"2018","unstructured":"Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Rev Gastroenterol Hepatol. 2018;. https:\/\/doi.org\/10.1080\/17474124.2018.1453356 .","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"5072_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","volume":"102","author":"N Mataki","year":"2007","unstructured":"Mataki N, Kikuchi K, Kawai T, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am J Gastroenterol. 2007;102:302\u2013312.","journal-title":"Am J Gastroenterol."},{"key":"5072_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1440-1827.2007.02129.x","volume":"57","author":"T Oikawa","year":"2007","unstructured":"Oikawa T, Takahashi H, Ishikawa T, et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int. 2007;57:485\u2013492.","journal-title":"Pathol Int."},{"key":"5072_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/jgh.12340","volume":"29","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Miyake Y, Matsushita H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 2014;29:110\u2013115.","journal-title":"J Gastroenterol Hepatol."},{"key":"5072_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/hepr.12305","volume":"44","author":"Y Miyake","year":"2014","unstructured":"Miyake Y, Yamamoto K, Matsushita H, et al. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol Res. 2014;44:1299\u20131307.","journal-title":"Hepatol Res."},{"key":"5072_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/00365521.2016.1233576","volume":"52","author":"K Aarslev","year":"2017","unstructured":"Aarslev K, Dige A, Greisen SR, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand J Gastroenterol. 2017;52:93\u201399.","journal-title":"Scand J Gastroenterol."},{"key":"5072_CR29","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/apt.13801","volume":"44","author":"H Gronbaek","year":"2016","unstructured":"Gronbaek H, Kreutzfeldt M, Kazankov K, et al. Single-centre experience of the macrophage activation marker soluble (s)CD163\u2014associations with disease activity and treatment response in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 2016;44:1062\u20131070.","journal-title":"Aliment Pharmacol Ther."},{"key":"5072_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365513.2011.626868","volume":"72","author":"HJ Moller","year":"2012","unstructured":"Moller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72:1\u201313.","journal-title":"Scand J Clin Lab Invest."},{"key":"5072_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/hep.26664","volume":"59","author":"DN Assis","year":"2014","unstructured":"Assis DN, Leng L, Du X, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology. 2014;59:580\u2013591.","journal-title":"Hepatology."},{"key":"5072_CR32","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s10620-016-4322-z","volume":"61","author":"DN Assis","year":"2016","unstructured":"Assis DN, Takahashi H, Leng L, et al. A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients. Dig Dis Sci. 2016;61:3506\u20133512.","journal-title":"Dig Dis Sci."},{"key":"5072_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","volume":"68","author":"K Migita","year":"2007","unstructured":"Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol. 2007;68:586\u2013591.","journal-title":"Hum Immunol."},{"key":"5072_CR34","doi-asserted-by":"publisher","first-page":"e3194","DOI":"10.1097\/MD.0000000000003194","volume":"95","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-Inducible protein-10 in autoimmune hepatitis. Medicine (Baltimore). 2016;95:e3194.","journal-title":"Medicine (Baltimore)."},{"key":"5072_CR35","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1053\/gast.1997.v112.pm9178696","volume":"112","author":"MD Strettell","year":"1997","unstructured":"Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028\u20132035.","journal-title":"Gastroenterology."},{"key":"5072_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hep.510250211","volume":"25","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317\u2013323.","journal-title":"Hepatology."},{"key":"5072_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/hep.21518","volume":"45","author":"S Yokosawa","year":"2007","unstructured":"Yokosawa S, Yoshizawa K, Ota M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology. 2007;45:384\u2013390.","journal-title":"Hepatology."},{"key":"5072_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2013.07.004","volume":"46","author":"GF Mells","year":"2013","unstructured":"Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun. 2013;46:41\u201354.","journal-title":"J Autoimmun."},{"key":"5072_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","volume":"147","author":"YS Boer de","year":"2014","unstructured":"de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147:443\u2013452.","journal-title":"Gastroenterology."},{"key":"5072_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/gene.2014.82","volume":"16","author":"NM Gerven van","year":"2015","unstructured":"van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16:247\u2013252.","journal-title":"Genes Immun."},{"key":"5072_CR41","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/jhg.2017.74","volume":"62","author":"T Umemura","year":"2017","unstructured":"Umemura T, Joshita S, Hamano H, et al. Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients. J Hum Genet. 2017;62:963\u2013967.","journal-title":"J Hum Genet."},{"key":"5072_CR42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1034\/j.1600-0676.2001.021004272.x","volume":"21","author":"CK Fox","year":"2001","unstructured":"Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 2001;21:272\u2013279.","journal-title":"Liver."},{"key":"5072_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1568-9972(02)00125-8","volume":"2","author":"J Bai","year":"2003","unstructured":"Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev. 2003;2:36\u201342.","journal-title":"Autoimmun Rev."},{"key":"5072_CR44","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1007\/s10620-014-3284-2","volume":"59","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci. 2014;59:2890\u20132904.","journal-title":"Dig Dis Sci."},{"key":"5072_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0168-8278(02)00266-0","volume":"37","author":"P Sanz-Cameno","year":"2002","unstructured":"Sanz-Cameno P, Medina J, Garcia-Buey L, et al. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol. 2002;37:723\u2013729.","journal-title":"J Hepatol."},{"key":"5072_CR46","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s10620-014-3267-3","volume":"59","author":"C Efe","year":"2014","unstructured":"Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014;59:3035\u20133042.","journal-title":"Dig Dis Sci."},{"key":"5072_CR47","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s10620-015-3526-y","volume":"60","author":"Y Beyazit","year":"2015","unstructured":"Beyazit Y, Kocak E, Tanoglu A, Kekilli M. Oxidative stress might play a role in low serum vitamin D associated liver fibrosis among patients with autoimmune hepatitis. Dig Dis Sci. 2015;60:1106\u20131108.","journal-title":"Dig Dis Sci."},{"key":"5072_CR48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/00365521.2014.974203","volume":"50","author":"Y Beyazit","year":"2015","unstructured":"Beyazit Y, Efe C, Tanoglu A, et al. Nitric oxide is a potential mediator of hepatic inflammation and fibrogenesis in autoimmune hepatitis. Scand J Gastroenterol. 2015;50:204\u2013210.","journal-title":"Scand J Gastroenterol."},{"key":"5072_CR49","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s10620-016-4247-6","volume":"61","author":"AJ Czaja","year":"2016","unstructured":"Czaja AJ. Nature and implications of oxidative and nitrosative stresses in autoimmune hepatitis. Dig Dis Sci. 2016;61:2784\u20132803.","journal-title":"Dig Dis Sci."},{"key":"5072_CR50","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646\u2013652.","journal-title":"J Hepatol."},{"key":"5072_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161\u2013167.","journal-title":"J Hepatol."},{"key":"5072_CR52","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1007\/s10620-016-4254-7","volume":"61","author":"AJ Montano-Loza","year":"2016","unstructured":"Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting hepatic fibrosis in autoimmune hepatitis. Dig Dis Sci. 2016;61:3118\u20133139.","journal-title":"Dig Dis Sci."},{"key":"5072_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3748\/wjg.v23.i5.859","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang J, Malik N, Yin M, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol. 2017;23:859\u2013868.","journal-title":"World J Gastroenterol."},{"key":"5072_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2005.06.008","volume":"11","author":"JH Meyers","year":"2005","unstructured":"Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med. 2005;11:362\u2013369.","journal-title":"Trends Mol Med."},{"key":"5072_CR55","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u20131252.","journal-title":"Nat Immunol."},{"key":"5072_CR56","first-page":"1","volume":"350","author":"C Zhu","year":"2011","unstructured":"Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol. 2011;350:1\u201315.","journal-title":"Curr Top Microbiol Immunol."},{"key":"5072_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1189\/jlb.1010591","volume":"91","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Ma CJ, Wang JM, et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14\u2009+\u2009monocytes. J Leukoc Biol. 2012;91:189\u2013196.","journal-title":"J Leukoc Biol."},{"key":"5072_CR58","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8\u2009+\u2009T cell exhaustion during chronic viral infection. Immunity. 2007;27:670\u2013684.","journal-title":"Immunity."},{"key":"5072_CR59","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u2013499.","journal-title":"Nat Immunol."},{"key":"5072_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","volume":"35","author":"A Schietinger","year":"2014","unstructured":"Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35:51\u201360.","journal-title":"Trends Immunol."},{"key":"5072_CR61","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612\u2013616.","journal-title":"Nature."},{"key":"5072_CR62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u2013499.","journal-title":"Nat Rev Immunol."},{"key":"5072_CR63","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/icb.2016.81","volume":"94","author":"EF McKinney","year":"2016","unstructured":"McKinney EF, Smith KG. T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunol Cell Biol. 2016;94:935\u2013942.","journal-title":"Immunol Cell Biol."},{"key":"5072_CR64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2016.09.005","volume":"43","author":"EF McKinney","year":"2016","unstructured":"McKinney EF, Smith KG. T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. Curr Opin Immunol. 2016;43:74\u201380.","journal-title":"Curr Opin Immunol."},{"key":"5072_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-016-0160-z","volume":"15","author":"K Catakovic","year":"2017","unstructured":"Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal. 2017;15:1.","journal-title":"Cell Commun Signal."},{"key":"5072_CR66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u2013242.","journal-title":"Immunol Rev."},{"key":"5072_CR67","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","volume":"7","author":"K Bardhan","year":"2016","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1\/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.","journal-title":"Front Immunol."},{"key":"5072_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1\/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27\u201341.","journal-title":"Cell Immunol."},{"key":"5072_CR69","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/hep.27131","volume":"60","author":"DA Mann","year":"2014","unstructured":"Mann DA. Epigenetics in liver disease. Hepatology. 2014;60:1418\u20131425.","journal-title":"Hepatology."},{"key":"5072_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/1744666X.2015.994507","volume":"11","author":"MA Jeffries","year":"2015","unstructured":"Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol. 2015;11:45\u201358.","journal-title":"Expert Rev Clin Immunol."},{"key":"5072_CR71","doi-asserted-by":"publisher","first-page":"e12899","DOI":"10.1111\/eci.12899","volume":"48","author":"AJ Czaja","year":"2018","unstructured":"Czaja AJ. Epigenetic changes and their implications in autoimmune hepatitis. Eur J Clin Invest. 2018;48:e12899.","journal-title":"Eur J Clin Invest."},{"key":"5072_CR72","first-page":"5153","volume":"8","author":"R Lin","year":"2015","unstructured":"Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8:5153\u20135160.","journal-title":"Int J Clin Exp Pathol."},{"key":"5072_CR73","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/hep.27998","volume":"62","author":"M Yuksel","year":"2015","unstructured":"Yuksel M, Wang Y, Tai N, et al. A novel \u201chumanized mouse\u201d model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015;62:1536\u20131550.","journal-title":"Hepatology."},{"key":"5072_CR74","doi-asserted-by":"publisher","first-page":"9257","DOI":"10.3748\/wjg.v22.i42.9257","volume":"22","author":"AJ Czaja","year":"2016","unstructured":"Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol. 2016;22:9257\u20139278.","journal-title":"World J Gastroenterol."},{"key":"5072_CR75","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri1111","volume":"3","author":"VK Kuchroo","year":"2003","unstructured":"Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003;3:454\u2013462.","journal-title":"Nat Rev Immunol."},{"key":"5072_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0065-2776(06)91006-2","volume":"91","author":"VK Kuchroo","year":"2006","unstructured":"Kuchroo VK, Meyers JH, Umetsu DT, DeKruyff RH. TIM family of genes in immunity and tolerance. Adv Immunol. 2006;91:227\u2013249.","journal-title":"Adv Immunol."},{"key":"5072_CR77","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1084\/jem.20050308","volume":"202","author":"S Chakravarti","year":"2005","unstructured":"Chakravarti S, Sabatos CA, Xiao S, et al. Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med. 2005;202:437\u2013444.","journal-title":"J Exp Med."},{"key":"5072_CR78","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20062498","volume":"204","author":"S Xiao","year":"2007","unstructured":"Xiao S, Najafian N, Reddy J, et al. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. 2007;204:1691\u20131702.","journal-title":"J Exp Med."},{"key":"5072_CR79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","volume":"26","author":"E Cao","year":"2007","unstructured":"Cao E, Zang X, Ramagopal UA, et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007;26:311\u2013321.","journal-title":"Immunity."},{"key":"5072_CR80","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2007.01.014","volume":"26","author":"C Santiago","year":"2007","unstructured":"Santiago C, Ballesteros A, Tami C, et al. Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity. 2007;26:299\u2013310.","journal-title":"Immunity."},{"key":"5072_CR81","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.immuni.2007.11.011","volume":"27","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, Karisola P, Pena-Cruz V, et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007;27:927\u2013940.","journal-title":"Immunity."},{"key":"5072_CR82","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/ni1186","volume":"6","author":"SE Umetsu","year":"2005","unstructured":"Umetsu SE, Lee WL, McIntire JJ, et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. 2005;6:447\u2013454.","journal-title":"Nat Immunol."},{"key":"5072_CR83","doi-asserted-by":"publisher","first-page":"12105","DOI":"10.1073\/pnas.1120914109","volume":"109","author":"S Xiao","year":"2012","unstructured":"Xiao S, Brooks CR, Zhu C, et al. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A. 2012;109:12105\u201312110.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR84","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1749-6632.2009.05137.x","volume":"1183","author":"DJ DiLillo","year":"2010","unstructured":"DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010;1183:38\u201357.","journal-title":"Ann N Y Acad Sci."},{"key":"5072_CR85","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","volume":"30","author":"C Mauri","year":"2012","unstructured":"Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221\u2013241.","journal-title":"Annu Rev Immunol."},{"key":"5072_CR86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2174\/156652412800620057","volume":"12","author":"JD Bouaziz","year":"2012","unstructured":"Bouaziz JD, Le Buanec H, Saussine A, Bensussan A, Bagot M. IL-10 producing regulatory B cells in mice and humans: state of the art. Curr Mol Med. 2012;12:519\u2013527.","journal-title":"Curr Mol Med."},{"key":"5072_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/cmi.2012.60","volume":"10","author":"M Yang","year":"2013","unstructured":"Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. Cell Mol Immunol. 2013;10:122\u2013132.","journal-title":"Cell Mol Immunol."},{"key":"5072_CR88","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.4049\/jimmunol.1402632","volume":"194","author":"S Xiao","year":"2015","unstructured":"Xiao S, Brooks CR, Sobel RA, Kuchroo VK. Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation. J Immunol. 2015;194:1602\u20131608.","journal-title":"J Immunol."},{"key":"5072_CR89","doi-asserted-by":"publisher","first-page":"14080","DOI":"10.1073\/pnas.0700326104","volume":"104","author":"M Gray","year":"2007","unstructured":"Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007;104:14080\u201314085.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1073\/pnas.1109173109","volume":"109","author":"K Miles","year":"2012","unstructured":"Miles K, Heaney J, Sibinska Z, et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A. 2012;109:887\u2013892.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR91","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1172\/JCI32451","volume":"118","author":"T Ueno","year":"2008","unstructured":"Ueno T, Habicht A, Clarkson MR, et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest. 2008;118:742\u2013751.","journal-title":"J Clin Invest."},{"key":"5072_CR92","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u2013541.","journal-title":"Nature."},{"key":"5072_CR93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.72.3.486","volume":"72","author":"T Imaizumi","year":"2002","unstructured":"Imaizumi T, Kumagai M, Sasaki N, et al. Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol. 2002;72:486\u2013491.","journal-title":"J Leukoc Biol."},{"key":"5072_CR94","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","volume":"185","author":"V Dardalhon","year":"2010","unstructured":"Dardalhon V, Anderson AC, Karman J, et al. Tim-3\/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b\u2009+\u2009Ly-6G\u2009+\u2009myeloid cells. J Immunol. 2010;185:1383\u20131392.","journal-title":"J Immunol."},{"key":"5072_CR95","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"JI Youn","year":"2008","unstructured":"Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791\u20135802.","journal-title":"J Immunol."},{"key":"5072_CR96","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","volume":"111","author":"K Movahedi","year":"2008","unstructured":"Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233\u20134244.","journal-title":"Blood."},{"key":"5072_CR97","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u2013174.","journal-title":"Nat Rev Immunol."},{"key":"5072_CR98","doi-asserted-by":"publisher","first-page":"e31524","DOI":"10.1371\/journal.pone.0031524","volume":"7","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender ZG, Sun J, Mishalian I, et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One. 2012;7:e31524.","journal-title":"PLoS One."},{"key":"5072_CR99","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.12688\/f1000research.9691.1","volume":"5","author":"JF Deniset","year":"2016","unstructured":"Deniset JF, Kubes P. Recent advances in understanding neutrophils. F1000Res. 2016;5:2912.","journal-title":"F1000Res"},{"key":"5072_CR100","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","volume":"171","author":"GJ Wright","year":"2003","unstructured":"Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171:3034\u20133046.","journal-title":"J Immunol."},{"key":"5072_CR101","doi-asserted-by":"publisher","first-page":"e1002374","DOI":"10.1371\/journal.ppat.1002374","volume":"7","author":"MA Fischer","year":"2011","unstructured":"Fischer MA, Davies ML, Reider IE, et al. CD11b(+), Ly6G(+) cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection. PLoS Pathog. 2011;7:e1002374.","journal-title":"PLoS Pathog."},{"key":"5072_CR102","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","volume":"184","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184:3106\u20133116.","journal-title":"J Immunol."},{"key":"5072_CR103","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","volume":"113","author":"M Nakayama","year":"2009","unstructured":"Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821\u20133830.","journal-title":"Blood."},{"key":"5072_CR104","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ni1185","volume":"6","author":"JH Meyers","year":"2005","unstructured":"Meyers JH, Chakravarti S, Schlesinger D, et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol. 2005;6:455\u2013464.","journal-title":"Nat Immunol."},{"key":"5072_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12038-016-9616-y","volume":"41","author":"S John","year":"2016","unstructured":"John S, Mishra R. Galectin-9: From cell biology to complex disease dynamics. J Biosci. 2016;41:507\u2013534.","journal-title":"J Biosci."},{"key":"5072_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/hep.29106","volume":"66","author":"L Golden-Mason","year":"2017","unstructured":"Golden-Mason L, Rosen HR. Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation. Hepatology. 2017;66:271\u2013279.","journal-title":"Hepatology."},{"key":"5072_CR107","doi-asserted-by":"publisher","first-page":"e38708","DOI":"10.1371\/journal.pone.0038708","volume":"7","author":"GM Vaitaitis","year":"2012","unstructured":"Vaitaitis GM, Wagner DH Jr. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One. 2012;7:e38708.","journal-title":"PLoS One."},{"key":"5072_CR108","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.4049\/jimmunol.173.12.7200","volume":"173","author":"R Morgan","year":"2004","unstructured":"Morgan R, Gao G, Pawling J, et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol. 2004;173:7200\u20137208.","journal-title":"J Immunol."},{"key":"5072_CR109","doi-asserted-by":"publisher","first-page":"20027","DOI":"10.1074\/jbc.M701890200","volume":"282","author":"A Grigorian","year":"2007","unstructured":"Grigorian A, Lee SU, Tian W, et al. Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem. 2007;282:20027\u201320035.","journal-title":"J Biol Chem."},{"key":"5072_CR110","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nri2417","volume":"8","author":"JD Marth","year":"2008","unstructured":"Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008;8:874\u2013887.","journal-title":"Nat Rev Immunol."},{"key":"5072_CR111","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.3748\/wjg.v19.i47.8831","volume":"19","author":"ML Bacigalupo","year":"2013","unstructured":"Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol. 2013;19:8831\u20138849.","journal-title":"World J Gastroenterol."},{"key":"5072_CR112","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1073\/pnas.93.13.6737","volume":"93","author":"RY Yang","year":"1996","unstructured":"Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996;93:6737\u20136742.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR113","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/35055582","volume":"409","author":"M Demetriou","year":"2001","unstructured":"Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5N-glycosylation. Nature. 2001;409:733\u2013739.","journal-title":"Nature."},{"key":"5072_CR114","doi-asserted-by":"publisher","first-page":"e48379","DOI":"10.1371\/journal.pone.0048379","volume":"7","author":"K Lv","year":"2012","unstructured":"Lv K, Zhang Y, Zhang M, Zhong M, Suo Q. Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low\/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One. 2012;7:e48379.","journal-title":"PLoS One."},{"key":"5072_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/mmr.2017.6606","volume":"16","author":"T Tadokoro","year":"2017","unstructured":"Tadokoro T, Morishita A, Sakamoto T, et al. Galectin9 ameliorates fulminant liver injury. Mol Med Rep. 2017;16:36\u201342.","journal-title":"Mol Med Rep."},{"key":"5072_CR116","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.4049\/jimmunol.170.7.3631","volume":"170","author":"Y Kashio","year":"2003","unstructured":"Kashio Y, Nakamura K, Abedin MJ, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol. 2003;170:3631\u20133636.","journal-title":"J Immunol."},{"key":"5072_CR117","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/glycob\/cwq214","volume":"21","author":"EW Su","year":"2011","unstructured":"Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology. 2011;21:1258\u20131265.","journal-title":"Glycobiology."},{"key":"5072_CR118","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","volume":"127","author":"M Seki","year":"2008","unstructured":"Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127:78\u201388.","journal-title":"Clin Immunol."},{"key":"5072_CR119","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.4049\/jimmunol.0803673","volume":"182","author":"S Sehrawat","year":"2009","unstructured":"Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT. Role of Tim-3\/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol. 2009;182:3191\u20133201.","journal-title":"J Immunol."},{"key":"5072_CR120","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1002\/med.20249","volume":"33","author":"VR Wiersma","year":"2013","unstructured":"Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease. Med Res Rev. 2013;33:E102\u2013E126.","journal-title":"Med Res Rev."},{"key":"5072_CR121","doi-asserted-by":"publisher","first-page":"e9504","DOI":"10.1371\/journal.pone.0009504","volume":"5","author":"JA Mengshol","year":"2010","unstructured":"Mengshol JA, Golden-Mason L, Arikawa T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010;5:e9504.","journal-title":"PLoS One."},{"key":"5072_CR122","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1172\/JCI67714","volume":"123","author":"HR Rosen","year":"2013","unstructured":"Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest. 2013;123:4121\u20134130.","journal-title":"J Clin Invest."},{"key":"5072_CR123","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.4049\/jimmunol.1202814","volume":"190","author":"ZH Tang","year":"2013","unstructured":"Tang ZH, Liang S, Potter J, et al. Tim-3\/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol. 2013;190:1788\u20131796.","journal-title":"J Immunol."},{"key":"5072_CR124","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.gastro.2014.11.041","volume":"148","author":"LJ Markwick","year":"2015","unstructured":"Markwick LJ, Riva A, Ryan JM, et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology. 2015;148:590\u2013602.","journal-title":"Gastroenterology."},{"key":"5072_CR125","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s10620-014-3473-z","volume":"60","author":"AJ Montano-Loza","year":"2014","unstructured":"Montano-Loza AJ, Czaja AJ. Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci. 2014;60:1528\u20131542.","journal-title":"Dig Dis Sci."},{"key":"5072_CR126","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/1744666X.2017.1319764","volume":"13","author":"AJ Czaja","year":"2017","unstructured":"Czaja AJ. Evolving paradigm for treatment of autoimmune hepatitis. Expert Rev Clin Immunol. 2017;13:781\u2013798.","journal-title":"Expert Rev Clin Immunol."},{"key":"5072_CR127","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205\u20132213.","journal-title":"J Exp Med."},{"key":"5072_CR128","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","volume":"77","author":"EJ Wherry","year":"2003","unstructured":"Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77:4911\u20134927.","journal-title":"J Virol."},{"key":"5072_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","volume":"322","author":"M Davoodzadeh Gholami","year":"2017","unstructured":"Davoodzadeh Gholami M, Kardar GA, Saeedi Y, et al. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 2017;322:1\u201314.","journal-title":"Cell Immunol."},{"key":"5072_CR130","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1172\/JCI26856","volume":"116","author":"DG Brooks","year":"2006","unstructured":"Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest. 2006;116:1675\u20131685.","journal-title":"J Clin Invest."},{"key":"5072_CR131","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","volume":"6","author":"J Lee","year":"2015","unstructured":"Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating exhausted T cells by blockade of the PD-1 pathway. For Immunopathol Dis Therap. 2015;6:7\u201317.","journal-title":"For Immunopathol Dis Therap."},{"key":"5072_CR132","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.1073\/pnas.0809818106","volume":"106","author":"SN Mueller","year":"2009","unstructured":"Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009;106:8623\u20138628.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR133","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","volume":"479\u2013480","author":"SM Kahan","year":"2015","unstructured":"Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology. 2015;479\u2013480:180\u2013193.","journal-title":"Virology."},{"key":"5072_CR134","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/v9100289","volume":"9","author":"M Bellon","year":"2017","unstructured":"Bellon M, Nicot C. Telomere dynamics in immune senescence and exhaustion triggered by chronic viral infection. Viruses. 2017;9:289.","journal-title":"Viruses."},{"key":"5072_CR135","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682\u2013687.","journal-title":"Nature."},{"key":"5072_CR136","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239\u2013245.","journal-title":"Nat Immunol."},{"key":"5072_CR137","doi-asserted-by":"publisher","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","volume":"110","author":"F Wei","year":"2013","unstructured":"Wei F, Zhong S, Ma Z, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A. 2013;110:E2480\u2013E2489.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR138","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8\u2009+\u2009T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29\u201337.","journal-title":"Nat Immunol."},{"key":"5072_CR139","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","volume":"40","author":"A Crawford","year":"2014","unstructured":"Crawford A, Angelosanto JM, Kao C, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity. 2014;40:289\u2013302.","journal-title":"Immunity."},{"key":"5072_CR140","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/eji.200425828","volume":"35","author":"KS Lang","year":"2005","unstructured":"Lang KS, Recher M, Navarini AA, et al. Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. Eur J Immunol. 2005;35:738\u2013745.","journal-title":"Eur J Immunol."},{"key":"5072_CR141","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8\u2009+\u2009T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417\u2013421.","journal-title":"Nature."},{"key":"5072_CR142","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105:15016\u201315021.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR143","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ni1268","volume":"6","author":"AM Intlekofer","year":"2005","unstructured":"Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8\u2009+\u2009T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005;6:1236\u20131244.","journal-title":"Nat Immunol."},{"key":"5072_CR144","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","volume":"338","author":"MA Paley","year":"2012","unstructured":"Paley MA, Kroy DC, Odorizzi PM, et al. Progenitor and terminal subsets of CD8\u2009+\u2009T cells cooperate to contain chronic viral infection. Science. 2012;338:1220\u20131225.","journal-title":"Science."},{"key":"5072_CR145","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1128\/JVI.68.12.8056-8063.1994","volume":"68","author":"M Matloubian","year":"1994","unstructured":"Matloubian M, Concepcion RJ, Ahmed R. CD4\u2009+\u2009T cells are required to sustain CD8\u2009+\u2009cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056\u20138063.","journal-title":"J Virol."},{"key":"5072_CR146","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","volume":"408","author":"J Parrish-Novak","year":"2000","unstructured":"Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57\u201363.","journal-title":"Nature."},{"key":"5072_CR147","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1189\/jlb.72.5.856","volume":"72","author":"J Parrish-Novak","year":"2002","unstructured":"Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002;72:856\u2013863.","journal-title":"J Leukoc Biol."},{"key":"5072_CR148","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.175.4.2261","volume":"175","author":"Y Li","year":"2005","unstructured":"Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175:2261\u20132269.","journal-title":"J Immunol."},{"key":"5072_CR149","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1126\/science.1176487","volume":"324","author":"LD Johnson","year":"2009","unstructured":"Johnson LD, Jameson SC. Immunology. A chronic need for IL-21. Science. 2009;324:1525\u20131526.","journal-title":"Science."},{"key":"5072_CR150","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1126\/science.1174182","volume":"324","author":"H Elsaesser","year":"2009","unstructured":"Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science. 2009;324:1569\u20131572.","journal-title":"Science."},{"key":"5072_CR151","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1126\/science.1175194","volume":"324","author":"JS Yi","year":"2009","unstructured":"Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009;324:1572\u20131576.","journal-title":"Science."},{"key":"5072_CR152","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/1389203033487063","volume":"4","author":"AL Wilkins","year":"2003","unstructured":"Wilkins AL, Yang W, Yang JJ. Structural biology of the cell adhesion protein CD2: from molecular recognition to protein folding and design. Curr Protein Pept Sci. 2003;4:367\u2013373.","journal-title":"Curr Protein Pept Sci."},{"key":"5072_CR153","doi-asserted-by":"publisher","first-page":"21865","DOI":"10.7448\/IAS.20.1.21865","volume":"20","author":"S Bolduan","year":"2017","unstructured":"Bolduan S, Koppensteiner H, Businger R, et al. T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naive chronic HIV-1 patients. J Int AIDS Soc. 2017;20:21865.","journal-title":"J Int AIDS Soc."},{"key":"5072_CR154","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaad.2014.01.914","volume":"70","author":"S Harcharik","year":"2014","unstructured":"Harcharik S, Bernardo S, Moskalenko M, et al. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. J Am Acad Dermatol. 2014;70:1036\u20131044.","journal-title":"J Am Acad Dermatol."},{"key":"5072_CR155","doi-asserted-by":"publisher","first-page":"20428","DOI":"10.1073\/pnas.0811139106","volume":"105","author":"DG Brooks","year":"2008","unstructured":"Brooks DG, Ha SJ, Elsaesser H, et al. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008;105:20428\u201320433.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2009.06.015","volume":"31","author":"R Tinoco","year":"2009","unstructured":"Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8\u2009+\u2009T cell deletion and viral persistence in vivo. Immunity. 2009;31:145\u2013157.","journal-title":"Immunity."},{"key":"5072_CR157","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1128\/JVI.00164-12","volume":"86","author":"L Garidou","year":"2012","unstructured":"Garidou L, Heydari S, Gossa S, McGavern DB. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J Virol. 2012;86:7060\u20137071.","journal-title":"J Virol."},{"key":"5072_CR158","first-page":"232","volume":"25","author":"T Boettler","year":"2012","unstructured":"Boettler T, Cheng Y, Ehrhardt K, von Herrath M. TGF-beta blockade does not improve control of an established persistent viral infection. Viral Immunol. 2012;25:232\u2013238.","journal-title":"Viral Immunol."},{"key":"5072_CR159","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","volume":"5","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5:ra46.","journal-title":"Sci Signal."},{"key":"5072_CR160","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015\u20133029.","journal-title":"J Exp Med."},{"key":"5072_CR161","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20131369.","journal-title":"Nat Med."},{"key":"5072_CR162","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u20131034.","journal-title":"J Exp Med."},{"key":"5072_CR163","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261\u2013268.","journal-title":"Nat Immunol."},{"key":"5072_CR164","doi-asserted-by":"publisher","first-page":"e1176653","DOI":"10.1080\/2162402X.2016.1176653","volume":"5","author":"CL Chen","year":"2016","unstructured":"Chen CL, Pan QZ, Zhao JJ, et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653.","journal-title":"Oncoimmunology."},{"key":"5072_CR165","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1084\/jem.193.7.839","volume":"193","author":"SY Tseng","year":"2001","unstructured":"Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193:839\u2013846.","journal-title":"J Exp Med."},{"key":"5072_CR166","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1073\/pnas.0931259100","volume":"100","author":"P Loke","year":"2003","unstructured":"Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100:5336\u20135341.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR167","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.4049\/jimmunol.172.8.4661","volume":"172","author":"KA Frauwirth","year":"2004","unstructured":"Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol. 2004;172:4661\u20134665.","journal-title":"J Immunol."},{"key":"5072_CR168","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","volume":"153","author":"CH Chang","year":"2013","unstructured":"Chang CH, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239\u20131251.","journal-title":"Cell."},{"key":"5072_CR169","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","volume":"194","author":"V Tkachev","year":"2015","unstructured":"Tkachev V, Goodell S, Opipari AW, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789\u20135800.","journal-title":"J Immunol."},{"key":"5072_CR170","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.","journal-title":"Nat Commun."},{"key":"5072_CR171","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4\u2009+\u2009T cell subsets. J Immunol. 2011;186:3299\u20133303.","journal-title":"J Immunol."},{"key":"5072_CR172","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cellimm.2005.07.007","volume":"235","author":"C Nielsen","year":"2005","unstructured":"Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235:109\u2013116.","journal-title":"Cell Immunol."},{"key":"5072_CR173","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","volume":"177","author":"B Wan","year":"2006","unstructured":"Wan B, Nie H, Liu A, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844\u20138850.","journal-title":"J Immunol."},{"key":"5072_CR174","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature05913","volume":"447","author":"A Bird","year":"2007","unstructured":"Bird A. Perceptions of epigenetics. Nature. 2007;447:396\u2013398.","journal-title":"Nature."},{"key":"5072_CR175","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.1787609","volume":"23","author":"SL Berger","year":"2009","unstructured":"Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781\u2013783.","journal-title":"Genes Dev."},{"key":"5072_CR176","first-page":"535","volume":"12","author":"BM Javierre","year":"2011","unstructured":"Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med. 2011;12:535\u2013545.","journal-title":"Discov Med."},{"key":"5072_CR177","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/cmi.2010.78","volume":"8","author":"F Meda","year":"2011","unstructured":"Meda F, Folci M, Baccarelli A, Selmi C. The epigenetics of autoimmunity. Cell Mol Immunol. 2011;8:226\u2013236.","journal-title":"Cell Mol Immunol."},{"key":"5072_CR178","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1101\/gr.154187.112","volume":"23","author":"H Heyn","year":"2013","unstructured":"Heyn H, Moran S, Hernando-Herraez I, et al. DNA methylation contributes to natural human variation. Genome Res. 2013;23:1363\u20131372.","journal-title":"Genome Res."},{"key":"5072_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08916934.2015.1086996","volume":"49","author":"CA Canas","year":"2016","unstructured":"Canas CA, Canas F, Bonilla-Abadia F, Ospina FE, Tobon GJ. Epigenetics changes associated to environmental triggers in autoimmunity. Autoimmunity. 2016;49:1\u201311.","journal-title":"Autoimmunity."},{"key":"5072_CR180","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/JCI69735","volume":"124","author":"JP Issa","year":"2014","unstructured":"Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest. 2014;124:24\u201329.","journal-title":"J Clin Invest."},{"key":"5072_CR181","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/epi-2016-0143","volume":"9","author":"MG Dozmorov","year":"2017","unstructured":"Dozmorov MG, Coit P, Maksimowicz-McKinnon K, Sawalha AH. Age-associated DNA methylation changes in naive CD4\u2009+\u2009T cells suggest an evolving autoimmune epigenotype in aging T cells. Epigenomics. 2017;9:429\u2013445.","journal-title":"Epigenomics."},{"key":"5072_CR182","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1101\/gr.157529.113","volume":"24","author":"S Maegawa","year":"2014","unstructured":"Maegawa S, Gough SM, Watanabe-Okochi N, et al. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res. 2014;24:580\u2013591.","journal-title":"Genome Res."},{"key":"5072_CR183","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794\u20131803.","journal-title":"Cancer."},{"key":"5072_CR184","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1002\/cncr.25204","volume":"116","author":"F Fang","year":"2010","unstructured":"Fang F, Balch C, Schilder J, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010;116:4043\u20134053.","journal-title":"Cancer."},{"key":"5072_CR185","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-9-192","volume":"9","author":"VV Konkankit","year":"2011","unstructured":"Konkankit VV, Kim W, Koya RC, et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas\/Fas ligand pathway. J Transl Med. 2011;9:192.","journal-title":"J Transl Med."},{"key":"5072_CR186","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","volume":"118","author":"JM Scandura","year":"2011","unstructured":"Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118:1472\u20131480.","journal-title":"Blood."},{"key":"5072_CR187","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12\u201327.","journal-title":"Cell."},{"key":"5072_CR188","doi-asserted-by":"publisher","first-page":"4302320","DOI":"10.1155\/2017\/4302320","volume":"2017","author":"W Zeng","year":"2017","unstructured":"Zeng W, Dai H, Yan M, et al. Decitabine-induced changes in human myelodysplastic syndrome cell line SKM-1 are mediated by FOXO3A activation. J Immunol Res. 2017;2017:4302320.","journal-title":"J Immunol Res."},{"key":"5072_CR189","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12016-009-8172-8","volume":"39","author":"M Szyf","year":"2010","unstructured":"Szyf M. Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol. 2010;39:62\u201377.","journal-title":"Clin Rev Allergy Immunol."},{"key":"5072_CR190","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4137\/GEG.S12144","volume":"5","author":"M Radic","year":"2013","unstructured":"Radic M, Muller S. Epigenetics of autoantigens: new opportunities for therapy of autoimmune diseases. Genet Epigenet. 2013;5:63\u201370.","journal-title":"Genet Epigenet."},{"key":"5072_CR191","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2217\/epi-2016-0144","volume":"9","author":"DF Tough","year":"2017","unstructured":"Tough DF, Prinjha RK. Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention. Epigenomics. 2017;9:573\u2013584.","journal-title":"Epigenomics."},{"key":"5072_CR192","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0961203313499419","volume":"23","author":"EC Somers","year":"2014","unstructured":"Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus. 2014;23:568\u2013576.","journal-title":"Lupus."},{"key":"5072_CR193","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40744-015-0014-y","volume":"2","author":"M Relle","year":"2015","unstructured":"Relle M, Foehr B, Schwarting A. Epigenetic aspects of systemic lupus erythematosus. Rheumatol Ther. 2015;2:33\u201346.","journal-title":"Rheumatol Ther."},{"key":"5072_CR194","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nbt.2487","volume":"31","author":"Y Liu","year":"2013","unstructured":"Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31:142\u2013147.","journal-title":"Nat Biotechnol."},{"key":"5072_CR195","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.34376","volume":"64","author":"X Lian","year":"2012","unstructured":"Lian X, Xiao R, Hu X, et al. DNA demethylation of CD40\u00a0l in CD4\u2009+\u2009T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum. 2012;64:2338\u20132345.","journal-title":"Arthritis Rheum."},{"key":"5072_CR196","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13148-015-0098-9","volume":"7","author":"A Lleo","year":"2015","unstructured":"Lleo A, Zhang W, Zhao M, et al. DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clin Epigenetics. 2015;7:61.","journal-title":"Clin Epigenetics."},{"key":"5072_CR197","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","volume":"145","author":"SK Murphy","year":"2013","unstructured":"Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:1076\u20131087.","journal-title":"Gastroenterology."},{"key":"5072_CR198","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-biochem-052610-091920","volume":"81","author":"H Cedar","year":"2012","unstructured":"Cedar H, Bergman Y. Programming of DNA methylation patterns. Annu Rev Biochem. 2012;81:97\u2013117.","journal-title":"Annu Rev Biochem."},{"key":"5072_CR199","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1101\/gr.100289.109","volume":"20","author":"BM Javierre","year":"2010","unstructured":"Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20:170\u2013179.","journal-title":"Genome Res."},{"key":"5072_CR200","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1128\/MCB.18.11.6538","volume":"18","author":"B Hendrich","year":"1998","unstructured":"Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998;18:6538\u20136547.","journal-title":"Mol Cell Biol."},{"key":"5072_CR201","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s003359901112","volume":"10","author":"B Hendrich","year":"1999","unstructured":"Hendrich B, Abbott C, McQueen H, et al. Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome. 1999;10:906\u2013912.","journal-title":"Mamm Genome."},{"key":"5072_CR202","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930\u2013935.","journal-title":"Science."},{"key":"5072_CR203","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.1210597","volume":"333","author":"S Ito","year":"2011","unstructured":"Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300\u20131303.","journal-title":"Science."},{"key":"5072_CR204","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.4161\/cc.10.16.17093","volume":"10","author":"JU Guo","year":"2011","unstructured":"Guo JU, Su Y, Zhong C, Ming GL, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle. 2011;10:2662\u20132668.","journal-title":"Cell Cycle."},{"key":"5072_CR205","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472\u2013479.","journal-title":"Nature."},{"key":"5072_CR206","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1093\/nar\/gkt035","volume":"41","author":"K Gunther","year":"2013","unstructured":"Gunther K, Rust M, Leers J, et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 2013;41:3010\u20133021.","journal-title":"Nucleic Acids Res."},{"key":"5072_CR207","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.cell.2013.03.011","volume":"153","author":"T Baubec","year":"2013","unstructured":"Baubec T, Ivanek R, Lienert F, Schubeler D. Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell. 2013;153:480\u2013492.","journal-title":"Cell."},{"key":"5072_CR208","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fgene.2014.00428","volume":"5","author":"R Menafra","year":"2014","unstructured":"Menafra R, Stunnenberg HG. MBD2 and MBD3: elusive functions and mechanisms. Front Genet. 2014;5:428.","journal-title":"Front Genet."},{"key":"5072_CR209","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nbt.1685","volume":"28","author":"A Portela","year":"2010","unstructured":"Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057\u20131068.","journal-title":"Nat Biotechnol."},{"key":"5072_CR210","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature14176","volume":"520","author":"T Baubec","year":"2015","unstructured":"Baubec T, Colombo DF, Wirbelauer C, et al. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature. 2015;520:243\u2013247.","journal-title":"Nature."},{"key":"5072_CR211","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/38444","volume":"389","author":"K Luger","year":"1997","unstructured":"Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997;389:251\u2013260.","journal-title":"Nature."},{"key":"5072_CR212","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/400_006","volume":"41","author":"MA Osley","year":"2006","unstructured":"Osley MA, Fleming AB, Kao CF. Histone ubiquitylation and the regulation of transcription. Results Probl Cell Differ. 2006;41:47\u201375.","journal-title":"Results Probl Cell Differ."},{"key":"5072_CR213","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2741\/1802","volume":"11","author":"J Wysocka","year":"2006","unstructured":"Wysocka J, Allis CD, Coonrod S. Histone arginine methylation and its dynamic regulation. Front Biosci. 2006;11:344\u2013355.","journal-title":"Front Biosci."},{"key":"5072_CR214","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48:491\u2013507.","journal-title":"Mol Cell."},{"key":"5072_CR215","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","volume":"70","author":"SY Roth","year":"2001","unstructured":"Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81\u2013120.","journal-title":"Annu Rev Biochem."},{"key":"5072_CR216","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"AJ Ruijter de","year":"2003","unstructured":"de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737\u2013749.","journal-title":"Biochem J."},{"key":"5072_CR217","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","volume":"983","author":"S Thiagalingam","year":"2003","unstructured":"Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84\u2013100.","journal-title":"Ann N Y Acad Sci."},{"key":"5072_CR218","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1172\/JCI67390","volume":"123","author":"JS Knight","year":"2013","unstructured":"Knight JS, Zhao W, Luo W, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest. 2013;123:2981\u20132993.","journal-title":"J Clin Invest."},{"key":"5072_CR219","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ng.159","volume":"40","author":"Y Kondo","year":"2008","unstructured":"Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40:741\u2013750.","journal-title":"Nat Genet."},{"key":"5072_CR220","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cgh.2006.10.015","volume":"5","author":"L Fisher","year":"2007","unstructured":"Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007;5:513\u2013520.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"5072_CR221","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12072-010-9194-2","volume":"4","author":"A Miroliaee","year":"2010","unstructured":"Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, et al. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int. 2010;4:634\u2013640.","journal-title":"Hepatol Int."},{"key":"5072_CR222","doi-asserted-by":"publisher","first-page":"1689S","DOI":"10.1093\/ajcn\/80.6.1689S","volume":"80","author":"HF DeLuca","year":"2004","unstructured":"DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S\u20131696S.","journal-title":"Am J Clin Nutr."},{"key":"5072_CR223","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","volume":"289","author":"AS Dusso","year":"2005","unstructured":"Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8\u2013F28.","journal-title":"Am J Physiol Renal Physiol."},{"key":"5072_CR224","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1359\/JBMR.041112","volume":"20","author":"S Kim","year":"2005","unstructured":"Kim S, Shevde NK, Pike JW. 1,25-dihydroxyvitamin D3 stimulates cyclic vitamin D receptor\/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res. 2005;20:305\u2013317.","journal-title":"J Bone Miner Res."},{"key":"5072_CR225","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1101\/gr.107920.110","volume":"20","author":"SV Ramagopalan","year":"2010","unstructured":"Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352\u20131360.","journal-title":"Genome Res."},{"key":"5072_CR226","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/jhep.2002.30084","volume":"35","author":"A Vogel","year":"2002","unstructured":"Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126\u2013131.","journal-title":"Hepatology."},{"key":"5072_CR227","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1440-1746.2005.03532.x","volume":"20","author":"L Fan","year":"2005","unstructured":"Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20:249\u2013255.","journal-title":"J Gastroenterol Hepatol."},{"key":"5072_CR228","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.2741\/1455","volume":"9","author":"Y Ohyama","year":"2004","unstructured":"Ohyama Y, Yamasaki T. Eight cytochrome P450s catalyze vitamin D metabolism. Front Biosci. 2004;9:3007\u20133018.","journal-title":"Front Biosci."},{"key":"5072_CR229","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.4049\/jimmunol.1102412","volume":"188","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte\/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188:2127\u20132135.","journal-title":"J Immunol."},{"key":"5072_CR230","first-page":"407","volume":"5","author":"KV Luong","year":"2013","unstructured":"Luong KV, Nguyen LT. The role of vitamin D in autoimmune hepatitis. J Clin Med Res. 2013;5:407\u2013415.","journal-title":"J Clin Med Res."},{"key":"5072_CR231","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337\u2013343.","journal-title":"Nature."},{"key":"5072_CR232","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307\u2013319.","journal-title":"Cell."},{"key":"5072_CR233","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934\u2013947.","journal-title":"Cell."},{"key":"5072_CR234","doi-asserted-by":"publisher","first-page":"17921","DOI":"10.1073\/pnas.1317023110","volume":"110","author":"SC Parker","year":"2013","unstructured":"Parker SC, Stitzel ML, Taylor DL, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A. 2013;110:17921\u201317926.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR235","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.1065173","volume":"295","author":"L Croce Di","year":"2002","unstructured":"Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 2002;295:1079\u20131082.","journal-title":"Science."},{"key":"5072_CR236","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871\u2013874.","journal-title":"Nature."},{"key":"5072_CR237","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/j.1365-2958.2006.05056.x","volume":"59","author":"EG Zoetendal","year":"2006","unstructured":"Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. Mol Microbiol. 2006;59:1639\u20131650.","journal-title":"Mol Microbiol."},{"key":"5072_CR238","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2217\/17460913.2.3.285","volume":"2","author":"CC Booijink","year":"2007","unstructured":"Booijink CC, Zoetendal EG, Kleerebezem M, de Vos WM. Microbial communities in the human small intestine: coupling diversity to metagenomics. Future Microbiol. 2007;2:285\u2013295.","journal-title":"Future Microbiol."},{"key":"5072_CR239","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220\u2013230.","journal-title":"Nature."},{"key":"5072_CR240","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1471-2180-9-123","volume":"9","author":"D Mariat","year":"2009","unstructured":"Mariat D, Firmesse O, Levenez F, et al. The Firmicutes\/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123.","journal-title":"BMC Microbiol."},{"key":"5072_CR241","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.1000097107","volume":"108","author":"MJ Claesson","year":"2011","unstructured":"Claesson MJ, Cusack S, O\u2019Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108:4586\u20134591.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR242","doi-asserted-by":"publisher","first-page":"e23035","DOI":"10.1371\/journal.pone.0023035","volume":"6","author":"J Jalanka-Tuovinen","year":"2011","unstructured":"Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One. 2011;6:e23035.","journal-title":"PLoS One."},{"key":"5072_CR243","doi-asserted-by":"publisher","first-page":"e0148952","DOI":"10.1371\/journal.pone.0148952","volume":"11","author":"GE Miller","year":"2016","unstructured":"Miller GE, Engen PA, Gillevet PM, et al. Lower neighborhood socioeconomic status associated with reduced diversity of the colonic microbiota in healthy adults. PLoS One. 2016;11:e0148952.","journal-title":"PLoS One."},{"key":"5072_CR244","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1017\/S0007114513002560","volume":"111","author":"SE Power","year":"2014","unstructured":"Power SE, O\u2019Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr. 2014;111:387\u2013402.","journal-title":"Br J Nutr."},{"key":"5072_CR245","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature07336","volume":"455","author":"L Wen","year":"2008","unstructured":"Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455:1109\u20131113.","journal-title":"Nature."},{"key":"5072_CR246","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.3390\/nu7115461","volume":"7","author":"ME Mejia-Leon","year":"2015","unstructured":"Mejia-Leon ME, Barca AM. Diet, microbiota and immune system in type 1 diabetes development and evolution. Nutrients. 2015;7:9171\u20139184.","journal-title":"Nutrients."},{"key":"5072_CR247","doi-asserted-by":"publisher","first-page":"e0137429","DOI":"10.1371\/journal.pone.0137429","volume":"10","author":"S Miyake","year":"2015","unstructured":"Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015;10:e0137429.","journal-title":"PLoS One."},{"key":"5072_CR248","doi-asserted-by":"publisher","first-page":"527696","DOI":"10.1155\/2015\/527696","volume":"2015","author":"R Rogier","year":"2015","unstructured":"Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696.","journal-title":"J Immunol Res."},{"key":"5072_CR249","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.MIB.0000200323.38139.c6","volume":"12","author":"H Sokol","year":"2006","unstructured":"Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:106\u2013111.","journal-title":"Inflamm Bowel Dis."},{"key":"5072_CR250","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1872-034X.2012.01088.x","volume":"43","author":"Y Miyake","year":"2013","unstructured":"Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res. 2013;43:139\u2013146.","journal-title":"Hepatol Res."},{"key":"5072_CR251","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2013.07.001","volume":"46","author":"J Henao-Mejia","year":"2013","unstructured":"Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun. 2013;46:66\u201373.","journal-title":"J Autoimmun."},{"key":"5072_CR252","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","volume":"139","author":"K Miura","year":"2010","unstructured":"Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323\u2013334.","journal-title":"Gastroenterology."},{"key":"5072_CR253","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hep.24341","volume":"54","author":"T Csak","year":"2011","unstructured":"Csak T, Ganz M, Pespisa J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133\u2013144.","journal-title":"Hepatology."},{"key":"5072_CR254","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179\u2013185.","journal-title":"Nature."},{"key":"5072_CR255","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/j.1478-3231.2011.02635.x","volume":"31","author":"T Mueller","year":"2011","unstructured":"Mueller T, Beutler C, Pico AH, et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int. 2011;31:1574\u20131588.","journal-title":"Liver Int."},{"key":"5072_CR256","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaut.2005.05.003","volume":"25","author":"AP Wang","year":"2005","unstructured":"Wang AP, Migita K, Ito M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun. 2005;25:85\u201391.","journal-title":"J Autoimmun."},{"key":"5072_CR257","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2004.11.005","volume":"128","author":"K Kikuchi","year":"2005","unstructured":"Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005;128:304\u2013312.","journal-title":"Gastroenterology."},{"key":"5072_CR258","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2007.03.012","volume":"47","author":"Y Honda","year":"2007","unstructured":"Honda Y, Yamagiwa S, Matsuda Y, et al. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol. 2007;47:404\u2013411.","journal-title":"J Hepatol."},{"key":"5072_CR259","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.27927","volume":"63","author":"JH Tabibian","year":"2016","unstructured":"Tabibian JH, O\u2019Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63:185\u2013196.","journal-title":"Hepatology."},{"key":"5072_CR260","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.24194","volume":"53","author":"S Shimoda","year":"2011","unstructured":"Shimoda S, Harada K, Niiro H, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology. 2011;53:1270\u20131281.","journal-title":"Hepatology."},{"key":"5072_CR261","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/hep.28122","volume":"62","author":"S Shimoda","year":"2015","unstructured":"Shimoda S, Hisamoto S, Harada K, et al. Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology. 2015;62:1817\u20131827.","journal-title":"Hepatology."},{"key":"5072_CR262","doi-asserted-by":"publisher","first-page":"17729","DOI":"10.1073\/pnas.0509006102","volume":"102","author":"SJ Turley","year":"2005","unstructured":"Turley SJ, Lee JW, Dutton-Swain N, Mathis D, Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci U S A. 2005;102:17729\u201317733.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR263","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3109\/00365529709011206","volume":"32","author":"CC Chan","year":"1997","unstructured":"Chan CC, Hwang SJ, Lee FY, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol. 1997;32:942\u2013946.","journal-title":"Scand J Gastroenterol."},{"key":"5072_CR264","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20632","volume":"41","author":"R Wiest","year":"2005","unstructured":"Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422\u2013433.","journal-title":"Hepatology."},{"key":"5072_CR265","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/apt.14324","volume":"46","author":"AJ Czaja","year":"2017","unstructured":"Czaja AJ. Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. Aliment Pharmacol Ther. 2017;46:920\u2013937.","journal-title":"Aliment Pharmacol Ther."},{"key":"5072_CR266","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.immuni.2013.08.013","volume":"39","author":"L Yurkovetskiy","year":"2013","unstructured":"Yurkovetskiy L, Burrows M, Khan AA, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39:400\u2013412.","journal-title":"Immunity."},{"key":"5072_CR267","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.1233521","volume":"339","author":"JG Markle","year":"2013","unstructured":"Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084\u20131088.","journal-title":"Science."},{"key":"5072_CR268","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4161\/gmic.29795","volume":"5","author":"JG Markle","year":"2014","unstructured":"Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes. 2014;5:485\u2013493.","journal-title":"Gut Microbes."},{"key":"5072_CR269","doi-asserted-by":"publisher","first-page":"17113","DOI":"10.1073\/pnas.0508643102","volume":"102","author":"AJ Souza de","year":"2005","unstructured":"de Souza AJ, Oriss TB, O\u2019Malley KJ, Ray A, Kane LP. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci U S A. 2005;102:17113\u201317118.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR270","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.178.1.211","volume":"178","author":"GT Miller","year":"1993","unstructured":"Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178:211\u2013222.","journal-title":"J Exp Med."},{"key":"5072_CR271","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","volume":"152","author":"GR Majeau","year":"1994","unstructured":"Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152:2753\u20132767.","journal-title":"J Immunol."},{"key":"5072_CR272","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.4049\/jimmunol.168.9.4462","volume":"168","author":"AJ Silva da","year":"2002","unstructured":"da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3\/IgG1 fusion protein, induces CD16 signaling and CD2\/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002;168:4462\u20134471.","journal-title":"J Immunol."},{"key":"5072_CR273","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1073\/pnas.0409569102","volume":"102","author":"F Chamian","year":"2005","unstructured":"Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102:2075\u20132080.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR274","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/nm.1993","volume":"15","author":"TA Weaver","year":"2009","unstructured":"Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009;15:746\u2013749.","journal-title":"Nat Med."},{"key":"5072_CR275","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","volume":"125","author":"MR Rigby","year":"2015","unstructured":"Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125:3285\u20133296.","journal-title":"J Clin Invest."},{"key":"5072_CR276","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.4049\/jimmunol.179.9.5886","volume":"179","author":"S Kuchen","year":"2007","unstructured":"Kuchen S, Robbins R, Sims GP, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4\u2009+\u2009T cell-B cell collaboration. J Immunol. 2007;179:5886\u20135896.","journal-title":"J Immunol."},{"key":"5072_CR277","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78:273\u2013304.","journal-title":"Annu Rev Biochem."},{"key":"5072_CR278","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","volume":"513","author":"L Zeng","year":"2002","unstructured":"Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 2002;513:124\u2013128.","journal-title":"FEBS Lett."},{"key":"5072_CR279","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1073\/pnas.1212264109","volume":"109","author":"HS Bandukwala","year":"2012","unstructured":"Bandukwala HS, Gagnon J, Togher S, et al. Selective inhibition of CD4\u2009+\u2009T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci U S A. 2012;109:14532\u201314537.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"5072_CR280","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728\u2013736.","journal-title":"Mol Cell."},{"key":"5072_CR281","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1189\/jlb.0107064","volume":"81","author":"E Balada","year":"2007","unstructured":"Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarres M. Transcript overexpression of the MBD2 and MBD4 genes in CD4\u2009+\u2009T cells from systemic lupus erythematosus patients. J Leukoc Biol. 2007;81:1609\u20131616.","journal-title":"J Leukoc Biol."},{"key":"5072_CR282","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/carcin\/bgh045","volume":"25","author":"PM Campbell","year":"2004","unstructured":"Campbell PM, Bovenzi V, Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis. 2004;25:499\u2013507.","journal-title":"Carcinogenesis."},{"key":"5072_CR283","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.celrep.2015.08.046","volume":"12","author":"JG Peeters","year":"2015","unstructured":"Peeters JG, Vervoort SJ, Tan SC, et al. Inhibition of super-enhancer activity in autoinflammatory site-derived T cells reduces disease-associated gene expression. Cell Rep. 2015;12:1986\u20131996.","journal-title":"Cell Rep."},{"key":"5072_CR284","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119\u20131123.","journal-title":"Nature."},{"key":"5072_CR285","doi-asserted-by":"publisher","first-page":"20812","DOI":"10.1074\/jbc.M211813200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem. 2003;278:20812\u201320820.","journal-title":"J Biol Chem."},{"key":"5072_CR286","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbrc.2015.02.074","volume":"459","author":"FP Reiter","year":"2015","unstructured":"Reiter FP, Hohenester S, Nagel JM, et al. 1,25-(OH)(2)-vitamin D(3) prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-\/-) model. Biochem Biophys Res Commun. 2015;459:227\u2013233.","journal-title":"Biochem Biophys Res Commun."},{"key":"5072_CR287","doi-asserted-by":"publisher","first-page":"G112","DOI":"10.1152\/ajpgi.00132.2013","volume":"308","author":"S Abramovitch","year":"2015","unstructured":"Abramovitch S, Sharvit E, Weisman Y, et al. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2015;308:G112\u2013G120.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"5072_CR288","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12331","volume":"500","author":"K Atarashi","year":"2013","unstructured":"Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232\u2013236.","journal-title":"Nature."},{"key":"5072_CR289","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1128\/AEM.07581-11","volume":"78","author":"P Lopez","year":"2012","unstructured":"Lopez P, Gonzalez-Rodriguez I, Sanchez B, et al. Interaction of Bifidobacterium bifidum LMG13195 with HT29 cells influences regulatory-T-cell-associated chemokine receptor expression. Appl Environ Microbiol. 2012;78:2850\u20132857.","journal-title":"Appl Environ Microbiol."},{"key":"5072_CR290","doi-asserted-by":"publisher","first-page":"7569431","DOI":"10.1155\/2016\/7569431","volume":"2016","author":"J Dolpady","year":"2016","unstructured":"Dolpady J, Sorini C, Di Pietro C, et al. Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment. J Diabetes Res. 2016;2016:7569431.","journal-title":"J Diabetes Res."},{"key":"5072_CR291","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1681\/ASN.2006101162","volume":"18","author":"RD Pawar","year":"2007","unstructured":"Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721\u20131731.","journal-title":"J Am Soc Nephrol."},{"key":"5072_CR292","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/2050640614520867","volume":"2","author":"F Scaldaferri","year":"2014","unstructured":"Scaldaferri F, Lopetuso LR, Petito V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for \u2018gut barrier protectors\u2019 in IBD? United Eur Gastroenterol J. 2014;2:113\u2013122.","journal-title":"United Eur Gastroenterol J."},{"key":"5072_CR293","first-page":"2112","volume":"30","author":"M Stone","year":"2003","unstructured":"Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol. 2003;30:2112\u20132122.","journal-title":"J Rheumatol."},{"key":"5072_CR294","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther. 2013;37:604\u2013612.","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5072-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:17:37Z","timestamp":1693631857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":294,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["5072"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5072-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author has no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}